摘要
目的:研究粉尘螨特异性免疫治疗对慢性荨麻疹患者CC型趋化因子表达水平的影响,探讨特异性免疫治疗的作用机制。方法:将64例粉尘螨过敏的慢性荨麻疹患者随机分为两组,分别采用粉尘螨注射液联合咪唑斯汀治疗或单用咪唑斯汀治疗。应用双抗体夹心酶联免疫吸附试验(ELISA)检测治疗前、后以及正常对照血清中调节激活正常T细胞表达和分泌的细胞因子(RANTES)及单核细胞趋化蛋白-1(MCP-1)的水平。结果:两组慢性荨麻疹患者治疗前血清RANTES和MCP-1的水平均显著高于各自治疗后第16周末(P分别<0.001和0.05)及正常对照(P均<0.001);联合治疗组在治疗后第16周末的RANTES和MCP-1水平以及每周咪唑斯汀用量的评分均显著低于单用咪唑斯汀组(P<0.01)。结论:RANTES和MCP-1在慢性荨麻疹的发病中起重要作用,特异性免疫治疗对慢性荨麻疹的治疗效果可能与其使RANTES和MCP-1下调的作用有关。
Objective： To investigate the effects of specific immunotherapy mizolastine combined with detmatophagoides farinae injection on the serum levels of CC chemokines in patients with chronic urticaria, including RANTES （regulated upon activation, normal T cell expressed and secreted） and monocyte chemoattractant protein-1（MCP-1）. Methods： Sixty-four chronic urticaria patients allergic to dermatophagoides farinae were randomly divided into two groups and received dermatophagoides farinae injection combined with mizolastine or only mizolastine respectively. The serum levels of RANTES and MCP-1 were measured by ELISA before and after treatment in patients and normal controls. Results： The serum levels of RANTES and MCP-1 were significantly higher in two groups of patients with chronic urticaria before treatment than those after 16 weeks treatment and those in normal controls, respectively. The serum level of RANTES and MCP-1 and the score of weekly mizolastine dosages after 16 weeks treatment were decreased significantly in the group treated with combination treatment than those in the group treated with mizolastine only. Conclusions： RANTES and MCP-1 might play an important role in the pathogenesis of chronic urticaria, which indicates that down-regulation of RANTES and MCP-1 may be involved in the mechanism of specific immunotherapy for chronic urticaira.
出处
《临床皮肤科杂志》
CAS
CSCD
北大核心
2007年第4期215-217,共3页
Journal of Clinical Dermatology
